Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Xtant Medical Holdings Q3 2026 Results: Net Loss of $3.56M

Xtant Medical Holdings reported total assets of $75.2 million as of September 30, 2026, a decrease from $94.1 million at year-end 2025, primarily driven by a reduction in cash and the settlement of a $10.5 million note receivable. The company is currently undergoing a strategic review by its Board of Directors and recently expanded its product portfolio with the exclusive distribution of HEMOBLAST Bellows.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue24.333.3
Gross profit13.722.0
Profit before tax-3.41.6
Net income-3.61.3
EPS (diluted, $ a share)$-0.03$0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-27.0%
Gross margin56.3%
Operating margin-12.5%
Source

10-Q filed with the SEC, NYSE: XTNT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Xtant Medical Holdings, Inc.: key numbers

Share price
$0.2098Close, Nov 16
Market cap
$29.5M
Shares outstanding
140.45MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Xtant Medical Holdings, Inc.

All →
7:06 AM ET 8-K
Financial Results

Xtant Medical Holdings Financial Results

Xtant Medical reported Q3 2026 revenue of $24.3 million, a decrease from $33.3 million in the prior year primarily due to divested businesses and the absence of wound care licensing revenue. The company's Board of Directors also announced a formal strategic review process to evaluate operational improvements, capital structure alternatives, and potential business combinations or transactions.

Term
Q3 2026

“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable.”

Stavros Vizirgianakis, Chairman of the Board

“The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process.”

Stavros Vizirgianakis, Chairman of the Board

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.